S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96

Fluidigm Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
60,126 shs
Average Volume
968,838 shs
Market Capitalization
$283.76 million
P/E Ratio
Dividend Yield
Price Target

Fluidigm MarketRank™ Forecast

Analyst Rating
Short Interest
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Acquiring Shares
$1.71 M Bought Last Quarter
Proj. Earnings Growth

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.95 out of 5 stars

Medical Sector

1110th out of 1,426 stocks

Analytical Instruments Industry

28th out of 33 stocks

Receive FLDM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fluidigm and its competitors with MarketBeat's FREE daily newsletter.

Fluidigm logo

About Fluidigm (NASDAQ:FLDM) Stock

Fluidigm Corporation creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

FLDM Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Analytical instruments
Life Sciences Tools & Services
Current Symbol
Year Founded

Company Calendar

Last Earnings
Fiscal Year End


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$130.58 million
Book Value
$1.24 per share


Free Float
Market Cap
$283.76 million

Fluidigm Frequently Asked Questions

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) issued its earnings results on Sunday, November, 7th. The medical research company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.04. The medical research company had revenue of $28.50 million for the quarter. Fluidigm had a negative net margin of 45.36% and a negative trailing twelve-month return on equity of 40.15%. During the same period last year, the firm earned ($0.03) earnings per share.
View Fluidigm's earnings history

Who are Fluidigm's key executives?

Fluidigm's management team includes the following people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 49, Pay $1.2M)
  • Mr. Vikram Jog, Chief Financial Officer (Age 66, Pay $667.25k)
  • Mr. Bradley Allen Kreger, Sr. VP of Global Operations (Age 47, Pay $560.62k)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48, Pay $481.58k)
  • Mr. Colin McCracken, Chief Commercial Officer (Age 48, Pay $734.78k)
  • Dr. Stephen R. Quake D.phil., Ph.D., Co-Founder & Chairman of Advisory Board (Age 52)
  • Mr. Andrew Quong, Chief Science Officer
  • Mr. Peter DeNardo, Investor Relations
  • Mark Spearman, Sr. Director of Corp. Communications
  • Ms. Angela Peters, Chief HR Officer

What is Chris Linthwaite's approval rating as Fluidigm's CEO?

30 employees have rated Fluidigm CEO Chris Linthwaite on Glassdoor.com. Chris Linthwaite has an approval rating of 78% among Fluidigm's employees.

What other stocks do shareholders of Fluidigm own?

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How much money does Fluidigm make?

Fluidigm (NASDAQ:FLDM) has a market capitalization of $0.00 and generates $130.58 million in revenue each year. The medical research company earns $-59,240,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Fluidigm have?

Fluidigm employs 615 workers across the globe.

How can I contact Fluidigm?

Fluidigm's mailing address is 2 Tower Place Ste 2000, South San Francisco CA, 94080. The official website for Fluidigm is www.fluidigm.com. The medical research company can be reached via phone at (650) 266-6000, via email at agnes.lee@fluidigm.com, or via fax at 650-871-7152.

This page (NASDAQ:FLDM) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.